维持性血透患者金黄色葡萄球菌菌血症21年趋势
该前瞻性队列纳入1995-2015年453例住院非中性粒细胞减少的维持性血透合并单微生物金黄色葡萄球菌菌血症患者,评估临床与细菌特征变化及结局关联。结果显示归因死亡率、持续性菌血症、转移性并发症及USA300克隆感染均逐年显著增加,而导管相关感染比例下降。
要点
- 维持性血透患者SAB归因死亡率每年增加0.45%。
- 持续性菌血症和转移性并发症分别每年增加0.86%和0.84%。
- 非血管通路来源感染者的SAB归因死亡风险更高(OR 3.20)。
核心结论
- 维持性血透患者SAB的临床和分子流行病学随时间变化,归因死亡率和并发症增加,尽管导管相关感染下降。
研究设计与样本
- 前瞻性队列研究,纳入1995-2015年453例住院非中性粒细胞减少的维持性血透合并单微生物SAB成人患者。
主要发现
- 归因死亡率每年增加0.45%(95%CI 0.36%-0.46%)。
- 持续性菌血症每年增加0.86%(95%CI 0.14%-1.55%)。
- 转移性并发症每年增加0.84%(95%CI 0.11%-1.56%)。
- USA300克隆感染每年增加1.47%(95%CI 0.33%-2.52%)。
- 非血管通路来源感染者SAB归因死亡OR为3.20(95%CI 1.36-7.55)。
关键数值与推荐
- 中心静脉导管作为可疑来源每年减少1.32%(95%CI -2.05至-0.56%)。
- 动静脉移植物作为可疑来源每年减少1.08%(95%CI -1.54至-0.56%)。
- 非血管通路来源每年增加1.89%(95%CI 1.29%-2.43%)。
- USA300感染与持续性菌血症相关OR为2.96(95%CI 1.12-7.83)。
- USA300与归因死亡(OR 0.83,95%CI 0.19-3.61)和转移性并发症(OR 1.34,95%CI 0.53-3.41)无显著关联。
临床怎么用
- 维持性血透患者发生SAB时需警惕非血管通路来源,其归因死亡风险更高。
- 应关注持续性菌血症和转移性并发症的增加趋势,加强监测与评估。
局限性
- 单中心住院队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Staphylococcus aureus (Saureus) bacteremia (SAB) is associated with morbidity and mortality in patients receiving maintenance hemodialysis (HD). We evaluated changes in clinical and bacterial characteristics, and their associations with clinical outcomes with SAB in this population over a 21-year period. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 453 hospitalized, non-neutropenic adults receiving maintenance HD who developed monomicrobial SAB between 1995 and 2015. EXPOSURE: Clinical characteristics and bacterial genotype. OUTCOME: All-cause and SAB-attributable mortality, persistent bacteremia, and metastatic complications. ANALYTICAL APPROACH: Proportions of participants experiencing each outcome were calculated overall and by calendar year. Secular trends were estimated using binomial risk regression, a generalized linear model with the log link function for a binomial outcome. Associations with outcomes were estimated using logistic regression. RESULTS: Over the 21-year study period, patients receiving maintenance HD experienced significant increases in age- and diabetes-adjusted SAB-attributable mortality (0.45% [95% CI, 0.36%-0.46%] per year), persistent bacteremia (0.86% [95% CI, 0.14%-1.55%] per year), metastatic complications (0.84% [95% CI, 0.11%-1.56%] per year), and infection with the virulent Saureus clone USA300 (1.47% [95% CI, 0.33%-2.52%] per year). Over time, the suspected source of SAB was less likely to be a central venous catheter (-1.32% [95% CI, -2.05 to-0.56%] per year) or arteriovenous graft (-1.08% [95% CI, -1.54 to-0.56] per year), and more likely to be a nonvascular access source (1.89% [95% CI, 1.29%-2.43%] per year). Patients with a nonvascular access suspected source of infection were more likely to die as a result of their S aureus infection (OR, 3.20 [95% CI, 1.36-7.55]). The increase in USA300 infections may have contributed to the observed increase in persistent bacteremia (OR, 2.96 [95% CI, 1.12-7.83]) but did not explain the observed increases in SAB-attributable mortality (OR, 0.83 [95% CI, 0.19-3.61]) or metastatic complications (OR, 1.34 [95% CI, 0.53-3.41]). LIMITATIONS: Single-center, inpatient cohort. CONCLUSIONS: The clinical and molecular epidemiology of SAB in patients receiving maintenance HD has changed over time, with an increase in SAB-attributable mortality and morbidity despite a decline in catheter-related infections.
引用
- Sinclair MR, Souli M, Ruffin F, et al. Staphylococcus aureus Bacteremia Among Patients Receiving Maintenance Hemodialysis: Trends in Clinical Characteristics and Outcomes. Am J Kidney Dis. 2021. PMID: 34303771. doi:10.1053/j.ajkd.2021.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。